ImmunityBio
As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense
TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment
ImmunityBio Trims Workforce Despite Recent FDA Approval for Anktiva
ImmunityBio, Anktiva, FDA approval, layoffs, financial challenges, bladder cancer treatment
ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges
ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy
ImmunityBio’s Anktiva Receives FDA Approval, Set to Rival Merck in Bladder Cancer Treatment
ImmunityBio, Anktiva, FDA approval, bladder cancer, Merck, cancer treatment, Patrick Soon-Shiong.
FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer
FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials
ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment
ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment